Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,738 DKK | +1.70% |
|
-4.70% | -19.89% |
28/06 | Would you like some more inflation? | ![]() |
28/06 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an enterprise value anticipated at 4.2 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.89% | 15.71B | - | ||
+15.81% | 122B | B+ | ||
+17.47% | 113B | B+ | ||
+17.38% | 26.22B | B | ||
-23.48% | 19.01B | B+ | ||
-18.38% | 15.22B | B | ||
-47.37% | 14.72B | A- | ||
+59.72% | 14.58B | C+ | ||
+5.43% | 13.84B | C+ | ||
+106.60% | 10.4B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GMAB Stock
- 0MGB Stock
- Ratings Genmab A/S